UB Paderborn / Katalog / Suche / in CDI

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

Scientific reports, 2019-07, Vol.9 (1), p.10634-10634, Article 10634

2019

Volltextzugriff (PDF)

Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models

Nature communications, 2023-04, Vol.14 (1), p.2068-2068, Article 2068

2023

Volltextzugriff (PDF)

Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

Cancer Immunology, Immunotherapy, 2007-05, Vol.56 (5), p.601-613

2007

Volltextzugriff (PDF)

Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

Scientific reports, 2020-07, Vol.10 (1), p.12733-12733, Article 12733

2020

Volltextzugriff (PDF)

A new era in anticancer peptide vaccines

Cancer, 2010-05, Vol.116 (9), p.2071-2080

2010

Volltextzugriff (PDF)

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine

Journal of clinical oncology, 2008-07, Vol.26 (20), p.3426-3433

2008

Volltextzugriff (PDF)

Induction of potent CD4+ T cell‐mediated antitumor responses by a helper HER‐2/neu peptide linked to the Ii‐Key moiety of the invariant chain

International journal of cancer, 2007-11, Vol.121 (9), p.2031-2041

2007

Volltextzugriff (PDF)

Inhibition of Tumorigenesis by a Cytosine-DNA, Methyltransferase, Antisense Oligodeoxynucleotide

Proceedings of the National Academy of Sciences - PNAS, 1997-01, Vol.94 (2), p.684-689

1997

Volltextzugriff (PDF)

Abstract 6597: Highly localized, inducible interleukin-12 release augments ICAM-1 CAR T cell activity against solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6597-6597

2020

Volltextzugriff (PDF)

Target selection and clinical chimeric antigen receptor T cell activity against solid tumors

iLABMED, 2023-06, Vol.1 (1), p.29-43

2023

Volltextzugriff (PDF)

Phase I study of AIC100 in relapsed and/or refractory advanced thyroid cancer and anaplastic thyroid cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.6093-6093

2022

Volltextzugriff (PDF)

Abstract 6598: Eradication of EpCAM expressing solid tumors by low-affinity CAR T cells

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6598-6598

2020

Volltextzugriff (PDF)

Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses

Cancer immunology research, 2021-10, Vol.9 (10), p.1158-1174

2021

Volltextzugriff (PDF)

Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein

Human gene therapy, 2005-02, Vol.16 (2), p.187-199

2005

Volltextzugriff (PDF)

Assessment of Bet v 1-Specific CD4+ T Cell Responses in Allergic and Nonallergic Individuals Using MHC Class II Peptide Tetramers

The Journal of immunology (1950), 2008-04, Vol.180 (7), p.4514-4522

2008

Volltextzugriff (PDF)

Bispecific CAR T cells against EpCAM and inducible ICAM-1 overcome antigen heterogeneity and generate superior anti-tumor responses

Cancer immunology research, 2021-08, Vol.9 (10), p.1158-1174

2021

Volltextzugriff (PDF)

Abstract 5568: Revitalization of affinity-tuned CAR T cells via antigen-dependent release of interleukin-12

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5568-5568

2022

Volltextzugriff (PDF)

Abstract 558: Focused IL-12 cytokine delivery enhances function of affinity-tuned and real-time tracked ICAM-1-specific CAR T cells in solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.558-558

2022

Volltextzugriff (PDF)

CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines

Vaccine, 2012-04, Vol.30 (18), p.2805-2810

2012

Volltextzugriff (PDF)

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3088-3088

2017

Volltextzugriff (PDF)

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer

Clinical cancer research, 2010-07, Vol.16 (13), p.3495-3506

2010

Volltextzugriff (PDF)

Abstract 5579: First-in-human study of ICAM-1-specific affinity tuned CAR T cells against advanced thyroid cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5579-5579

2022

Volltextzugriff (PDF)

Effect of immunization with the ii-key modified HER2/neu(776-790) (AE37) peptide vaccine on pre-existent immunity to PSA in HLA-A24+ prostate cancer patients: Association with increased AE37-specific immunologic responses

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e15125-e15125

2012

Volltextzugriff (PDF)

Effect of immunization with Ii-key modified HER2 (776-790) peptide vaccine (AE37) on immunologic responses in prostate cancer patients

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e16037-e16037

2013

Volltextzugriff (PDF)

Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.638-638

2014

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models

Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

Publisher Correction: Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

A new era in anticancer peptide vaccines

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine

Induction of potent CD4+ T cell‐mediated antitumor responses by a helper HER‐2/neu peptide linked to the Ii‐Key moiety of the invariant chain

Inhibition of Tumorigenesis by a Cytosine-DNA, Methyltransferase, Antisense Oligodeoxynucleotide

Abstract 6597: Highly localized, inducible interleukin-12 release augments ICAM-1 CAR T cell activity against solid tumors

Target selection and clinical chimeric antigen receptor T cell activity against solid tumors

Phase I study of AIC100 in relapsed and/or refractory advanced thyroid cancer and anaplastic thyroid cancer

Abstract 6598: Eradication of EpCAM expressing solid tumors by low-affinity CAR T cells

Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses

Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein

Assessment of Bet v 1-Specific CD4+ T Cell Responses in Allergic and Nonallergic Individuals Using MHC Class II Peptide Tetramers

Bispecific CAR T cells against EpCAM and inducible ICAM-1 overcome antigen heterogeneity and generate superior anti-tumor responses

Abstract 5568: Revitalization of affinity-tuned CAR T cells via antigen-dependent release of interleukin-12

Abstract 558: Focused IL-12 cytokine delivery enhances function of affinity-tuned and real-time tracked ICAM-1-specific CAR T cells in solid tumors

CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer

Abstract 5579: First-in-human study of ICAM-1-specific affinity tuned CAR T cells against advanced thyroid cancer

Effect of immunization with the ii-key modified HER2/neu(776-790) (AE37) peptide vaccine on pre-existent immunity to PSA in HLA-A24+ prostate cancer patients: Association with increased AE37-specific immunologic responses

Effect of immunization with Ii-key modified HER2 (776-790) peptide vaccine (AE37) on immunologic responses in prostate cancer patients

Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients

Suchergebnisse filtern